CN106748666A - 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 - Google Patents
一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 Download PDFInfo
- Publication number
- CN106748666A CN106748666A CN201611092814.8A CN201611092814A CN106748666A CN 106748666 A CN106748666 A CN 106748666A CN 201611092814 A CN201611092814 A CN 201611092814A CN 106748666 A CN106748666 A CN 106748666A
- Authority
- CN
- China
- Prior art keywords
- bibenzyl
- extract
- aglaia odorata
- aglaia
- odorata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 15
- 208000008589 Obesity Diseases 0.000 title claims abstract description 10
- 235000020824 obesity Nutrition 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000002218 hypoglycaemic effect Effects 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title abstract description 8
- 240000000595 Aglaia odorata Species 0.000 claims abstract description 35
- 235000010887 Aglaia odorata Nutrition 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 241000730318 Aglaia abbreviata Species 0.000 claims abstract description 7
- 235000013402 health food Nutrition 0.000 claims abstract description 5
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000003208 petroleum Substances 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000002024 ethyl acetate extract Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000001641 gel filtration chromatography Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 206010018473 Glycosuria Diseases 0.000 claims 1
- 241000158728 Meliaceae Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 239000013641 positive control Substances 0.000 abstract description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 abstract description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 abstract description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 abstract description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 229940100243 oleanolic acid Drugs 0.000 abstract description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 abstract description 3
- 108090000371 Esterases Proteins 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FYKHWKNFKLTGNX-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1.OC1=CC=C([N+]([O-])=O)C=C1 FYKHWKNFKLTGNX-UHFFFAOYSA-N 0.000 description 1
- KBOQXVVZFSWICE-FIJLXMTKSA-N 5-[(8R,9S,10R,13R,14S,17R)-14-hydroxy-10,13-dimethyl-1,2,7,8,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CCC=CC5=CC4)C)CC[C@@]32C)C=CC(=O)OC=1 KBOQXVVZFSWICE-FIJLXMTKSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- -1 tyrosine ester Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
- C07C37/685—Processes comprising at least two steps in series
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及医药技术领域，涉及从中国碧绿米仔兰Aglaia abbreviata C.Y.Wu叶片中提取分离得到的、具有降血糖功能的新天然药物，该药物为联苄类化合物联苄米仔兰素D(aglaiabbrevin D)。体外PTP1B抑制试验表明，该化合物对蛋白络氨酸酯酶1B(PTP1B)具有显著抑制活性，其活性强于阳性对照药物齐墩果酸，因此可制成药物制剂作为PTP1B抑制剂，用于治疗糖尿病、肥胖症及其并发症，也可以制造有益于糖尿病患者或肥胖患者的保健食品。
Description
技术领域
本发明涉及医药技术领域，涉及从中国碧绿米仔兰Aglaia abbreviata C.Y.Wu叶片中提取分离得到的、具有降血糖功能的新天然药物，该药物为联苄类化合物联苄米仔兰素D(aglaiabbrevin D)。可制成药物制剂作为PTP1B抑制剂，用于治疗糖尿病、肥胖症及其并发症，也可以制造有益于糖尿病患者或肥胖患者的保健食品。
背景技术
糖尿病(diabetes mellitus)是一组由遗传和环境因素相互作用而引起的临床综合症。目前，一般将糖尿病分为两类，I-型糖尿病(胰岛素依赖型糖尿病，insulin-dependent diabetes mellitus，IDDM)与II-型糖尿病(非胰岛素依赖型糖尿病，non-insulin-dependent diabetes mellitus，NIDDM)。糖尿病中90％以上是II-型糖尿病。
II-型糖尿病的特点是胰岛素敏感组织如骨骼肌、肝、脂肪组织对胰岛素作用的抵抗。蛋白酪氨酸磷酸酯酶(PTPases)在平衡细胞内胰岛素作用通路中相关蛋白酪氨酸磷酸化水平中的作用越来越受到重视，成为治疗II-型糖尿病的新途径。PTPase包括一大族跨膜(受体型)和胞内(非受体型)酶，参与调控一系列重要生命过程。目前，对PTPase在胰岛素通路中受体或受体后环节影响正常胰岛素作用的研究，主要集中在LAR-PTPase、SHPTP-2、PTP1B。
PTP1B是第一个被鉴定的蛋白酪氨酸磷酸酯酶(protein tyrosinephosphatase),通过PTP1B剔除的老鼠实验表明,PTP1B通过对胰岛素受体的脱磷酰化，进而在调节胰岛素敏感性和脂肪代谢过程中起着非常重要的作用。因而，选择性的、高活性的PTP1B抑制剂在II-型糖尿病、肥胖症及其并发症的治疗中有重要的价值。
发明内容
本发明是从中国碧绿米仔兰(A.abbreviata)叶片中提取分离得到的、具有降血糖作用的新联苄类化合物联苄米仔兰素D(aglaiabbrevin D)。经药理试验研究表明，该化合物对蛋白络氨酸磷酸酯酶1B(PTP1B)具有显著抑制活性，其活性强于阳性对照药齐墩果酸。
因此，本发明的一个目的是提供新的联苄类化合物联苄米仔兰素D。
本发明的另一个目的是提供所述联苄米仔兰素D的制备方法。
本发明的进一步目的是提供所述联苄米仔兰素D的用途。具体地说，所述联苄米仔兰素D在制备蛋白酪氨酸磷酸酯酶1B(PTP1B)抑制剂的药物中的应用，进一步在制备治疗糖尿病、肥胖症及其并发症的药物或保健食品中的应用。
根据本发明的第一个目的，本发明首次从碧绿米仔兰叶片中发现了联苄米仔兰素D，其化学结构如下所示：
根据本发明的第二个目的，本发明提供所述联苄米仔兰素D的制备方法，它是从碧绿米仔兰叶片中分离得到的，具体步骤如下：
1)制备提取物浸膏
将粉碎的碧绿米仔兰(A.abbreviata)叶片用乙醇按常规渗漉提取，得提取液，将提取液减压浓缩回收乙醇，得粗浸膏；
2)分离纯化
(1)将上述粗浸膏分散于水中成混悬液，将混悬液依次用石油醚、乙酸乙酯和正丁醇萃取，所得萃取液浓缩分别得到石油醚提取浸膏、乙酸乙酯提取浸膏和正丁醇提取浸膏；
(2)将乙酸乙酯浸膏进行硅胶柱层析，以石油醚/丙酮梯度洗脱，根据TLC显色合并相似流份得到4个组分A、B、C、D；其中组分B即石油醚/丙酮体积比8:2和7:3洗脱部分经Sephadex LH-20凝胶柱层析【层析柱规格：4.0(直径)×120(长度)cm；Sephadex LH-20凝胶干重：150g】，以二氯甲烷/甲醇体积比1:1洗脱，根据TLC显色合并相似流份得到6个组分(B1-B6)；组份B3即二氯甲烷/甲醇体积比1:1洗脱体积为90～120mL洗脱部分，再经硅胶柱层析，以石油醚/丙酮体积比75:25洗脱，最后经制备型HPLC，以甲醇/水80:20体积比洗脱，得到本发明化合物联苄米仔兰素D。
在上述制备方法中，在制备提取物浸膏步骤中，所述提取采用的乙醇为95％乙醇。
在上述制备方法中，在分离步骤中，石油醚/丙酮梯度洗脱的浓度依次为体积比100:0、90:10、80:20、70:30、50:50、30:70和0:100。
在上述制备方法中，在分离步骤中，所述制备型HPLC的色谱柱的填料为RP-18。
根据本发明的第三个目的，本发明提供了所述联苄米仔兰素D在制备PTP1B抑制剂、糖尿病药物、肥胖症药物的用途。以及制备用于糖尿病患者或肥胖患者保健食品的用途。
为了达到应用目的，可以制成片剂、胶囊、颗粒剂、口服液、缓释制剂、控释制剂、纳米制剂或注射剂等形式。
本发明对所得联苄米仔兰素D进行了体外PTP1B抑制试验，结果表明该化合物对PTP1B有明显的抑制活性。因此，可用来制备PTP1B抑制剂，用于治疗糖尿病、肥胖症及其并发症。
附图说明
图1 PTP1B抑制活性测试原理
具体实施方式
在如下的实施例中所指的联苄米仔兰素D的化学结构式(结构式中的阿拉伯数字是化学结构中碳原子的标位)：
实施例1所述联苄米仔兰素D的制备
1.制备碧绿米仔兰叶片提取物浸膏
(1)制备提取液
将粉碎的中国碧绿米仔兰(A.abbreviata)叶片(采自云南西双版纳)7.8kg(干重)分别用40L 95％乙醇渗漉提取三次，每次渗漉2天，合并提取液；
(2)制备提取物浸膏
将上述提取液在温度≤45℃减压浓缩回收乙醇，得粗浸膏530g；
2.分离纯化
1)将上述粗浸膏分散于6L水中成混悬液，将混悬液依次用石油醚(4L)、乙酸乙酯(4L)和正丁醇(2L)分别萃取三次，所得萃取液减压浓缩分别得到石油醚提取浸膏(58g)、乙酸乙酯提取浸膏(186g)和正丁醇提取浸膏(152g)；
2)将乙酸乙酯浸膏进行硅胶柱层析，以石油醚/丙酮梯度洗脱；梯度洗脱的浓度依次为体积比100:0、90:10、80:20、70:30、50:50、30:70和0:100，根据TLC显色合并相似流份得到4个组分(A、B、C、D)；
3)组分B即石油醚/丙酮体积比8:2和7:3洗脱部分经Sephadex LH-20凝胶柱层析【层析柱规格：4.0(直径)×120(长度)cm；Sephadex LH-20凝胶干重：150g】，以二氯甲烷/甲醇体积比1:1洗脱，根据TLC显色合并相似流份得到6个组分(B1-B6)；
4)组份B3，即二氯甲烷/甲醇体积比1:1洗脱体积为90～120mL洗脱部分，再经硅胶柱层析，以石油醚/丙酮体积比75:25洗脱，最后经制备型HPLC(色谱柱的填料为RP-18)，以甲醇/水体积比80:20洗脱，流速为3.5mL/min，保留时间为11.5min，得到本发明化合物联苄米仔兰素D，经鉴定为新化合物。
3.结构鉴定
按常规经NMR、HRESIMS、UV及IR等多种现代光谱技术，确定了化合物联苄米仔兰素D的化学结构，其理化性质如下：
黄色粉末,分子式为C24H30O3；
紫外光谱UV(MeOH)λmax(logε):216(4.33),232(3.98),285(3.72)nm；
红外光谱IR(KBr)νmax:3320,1612,1515,1420,1203cm–1；
高分辨质谱HR-ESI-MS m/z 365.2114[M–H]–(calcd for C24H29O3 –,365.2117)；
核磁共振氢谱1H NMR(600MHz)及核磁共振碳谱13C NMR(150MHz)数据见表一
表一 所述联苄米仔兰素D的1H和13C NMR(ppm in CDCl3)
实施例2 PTP1B抑制活性的测试：
测试原理：见图1。利用分子生物学手段在大肠杆菌系统表达人源蛋白络氨酸磷酸酯酶1B(hPTP1B)催化结构域，经纯化后的hPTP1B重组蛋白能水解底物对硝基苯磷酸(p-Nitrophenyl phosphate，pNPP)的磷脂键，得到黄色可溶产物对硝基苯酚(p-Nitrophenol)，该产物在410nm处有很强的光吸收，因此可以直接检测410nm处光吸收的变化及观察酶的活性变化以及化合物对酶活性的抑制情况。
标准的测活体系：10mM Tris.Cl三(羟甲基)氨基甲烷盐酸盐)，pH7.6，10mM pNPP，2％DMSO，100nM hPTP1B。
观察指标：动态测定波长为410nm处的光吸收，时间为3分钟，其动力学曲线一级反应的斜率作为酶的活性指标。
试验方法：用于筛选的蛋白酪氨酸磷酸酯酶PTP1B是从大肠杆菌中表达并纯化的GST融合蛋白。采用紫外适用底物对硝基苯磷酸(pNPP)，观察不同浓度对重组酶的活性的抑制作用，以初步评价化合物的药用效果。临用前将样品溶于DMSO配成适当浓度，3倍稀释，7个稀释度，设置三复孔，取2μL样品溶液加入96孔板，然后加入88μL assay mix(assaybuffer，pNPP，H2O)，再加入10μL PTP1B。将96孔板置于VERSAmax上动态检测波长为410nm处检测光吸收值，时间为3分钟。
实验结果的评判与解释：
筛选结果是化合物浓度为20μg/ml时对酶活性的百分抑制率，抑制率高于50％时，按常规筛选(将抑制率高于50％的被检测化合物稀释成不同的浓度，依上述测试方法进行反应，所有试验均设置复孔)得出IC50，阳性对照齐墩果酸的IC50为2.74±0.20μM。
实验结果：本发明化合物联苄米仔兰素D对PTP1B酶抑制活性的IC50为2.44±0.35μM。
实验结论：通过分子生物学试验，可以看出化合物联苄米仔兰素D对蛋白络氨酸酯酶1B(PTP1B)显著的抑制活性，其活性强于阳性对照药物齐墩果酸。因此，本发明的联苄米仔兰素D可用于制备糖尿病、肥胖症及其并发症的药物中。
Claims (5)
1.一种具有降血糖作用的联苄米仔兰素D，其特征在于具有如下化学结构：
2.根据权利要求1所述的联苄米仔兰素D，其特征在于所述的化合物是从楝科植物碧绿米仔兰中得到，碧绿米仔兰学名是Aglaia abbreviata C.Y.Wu。
3.权利要求1所述联苄米仔兰素D，其制备步骤如下：
1)制备提取物浸膏
将粉碎的碧绿米仔兰(A.abbreviata)叶片用乙醇按常规渗漉提取，得提取液，将提取液减压浓缩回收乙醇，得粗浸膏；
2)分离纯化
(1)将上述粗浸膏分散于水中成混悬液，将混悬液依次用石油醚、乙酸乙酯和正丁醇萃取，所得萃取液浓缩分别得到石油醚提取浸膏、乙酸乙酯提取浸膏和正丁醇提取浸膏；
(2)将乙酸乙酯浸膏进行硅胶柱层析，以石油醚/丙酮梯度洗脱，根据TLC显色合并相似流份得到4个组分A、B、C、D；其中组分B即石油醚/丙酮体积比8:2和7:3洗脱部分经SephadexLH-20凝胶柱层析(层析柱规格：4.0(直径)×120(长度)cm；Sephadex LH-20凝胶干重：150g)，以二氯甲烷/甲醇体积比1:1洗脱，根据TLC显色合并相似流份得到6个组分(B1-B6)；组份B3即二氯甲烷/甲醇体积比1:1洗脱体积为90～120mL洗脱部分，再经硅胶柱层析，以石油醚/丙酮体积比75:25洗脱，最后经制备型HPLC，以甲醇/水80:20体积比洗脱，得到本发明化合物联苄米仔兰素D；
在制备提取物浸膏步骤中，所述提取采用的乙醇为95％乙醇；
在分离步骤中，石油醚/丙酮梯度洗脱的浓度依次为体积比100:0、90:10、80:20、70:30、50:50、30:70和0:100；
在分离步骤中，所述制备型HPLC的色谱柱的填料为RP-18。
4.权利要求1所述的联苄米仔兰素D作为药物的活性成分，可制成片剂、胶囊、颗粒剂、口服液、缓释制剂、控释制剂、纳米制剂或注射剂作为PTP1B抑制剂，用于在制备治疗糖尿病、肥胖症及其并发症药物中的应用。
5.根据权利要求1所述的联苄米仔兰素D作为保健品的活性成分，制备用于糖尿病患者或肥胖患者保健食品的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611092814.8A CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611092814.8A CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106748666A true CN106748666A (zh) | 2017-05-31 |
| CN106748666B CN106748666B (zh) | 2021-01-05 |
Family
ID=58913762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611092814.8A Expired - Fee Related CN106748666B (zh) | 2016-12-01 | 2016-12-01 | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106748666B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111153883A (zh) * | 2020-01-17 | 2020-05-15 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
| CN111302942A (zh) * | 2020-04-09 | 2020-06-19 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
| CN113388563A (zh) * | 2021-06-01 | 2021-09-14 | 南昌大学 | 一种具有降糖作用的大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
| CN113416683A (zh) * | 2021-06-01 | 2021-09-21 | 南昌大学 | 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
| CN113461532A (zh) * | 2021-07-05 | 2021-10-01 | 南昌大学 | 一种具有降血糖作用的黑桑素a及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002014252A2 (en) * | 2000-08-16 | 2002-02-21 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
| US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
-
2016
- 2016-12-01 CN CN201611092814.8A patent/CN106748666B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002014252A2 (en) * | 2000-08-16 | 2002-02-21 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
| US6410596B1 (en) * | 2000-08-16 | 2002-06-25 | Insmed Incorporated | Compositions containing hypoglycemically active stillbenoids |
Non-Patent Citations (1)
| Title |
|---|
| TOSHINORI ASAKAWA等: "PRENYL BIBENZYLS FROM THE LIVER WORT RADULA KOJANA", 《PHYTOCHEMISTRY》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111153883A (zh) * | 2020-01-17 | 2020-05-15 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
| CN111153883B (zh) * | 2020-01-17 | 2022-04-08 | 中国热带农业科学院热带生物技术研究所 | 一种混元萜类化合物Verruculide B4及其制备方法和应用 |
| CN111302942A (zh) * | 2020-04-09 | 2020-06-19 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
| CN111302942B (zh) * | 2020-04-09 | 2022-03-01 | 中国热带农业科学院热带生物技术研究所 | 具有ptp1b抑制活性的化合物及其应用 |
| CN113388563A (zh) * | 2021-06-01 | 2021-09-14 | 南昌大学 | 一种具有降糖作用的大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
| CN113416683A (zh) * | 2021-06-01 | 2021-09-21 | 南昌大学 | 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用 |
| CN113461532A (zh) * | 2021-07-05 | 2021-10-01 | 南昌大学 | 一种具有降血糖作用的黑桑素a及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106748666B (zh) | 2021-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106748666A (zh) | 一种降血糖天然药物及其制备糖尿病或肥胖症药物用途 | |
| Bu et al. | α‐glucosidase inhibition and the in vivo hypoglycemic effect of butyl‐isobutyl‐phthalate derived from the Laminaria japonica rhizoid | |
| Fernandez et al. | Isoquercitrin from Argemone platyceras inhibits carbachol and leukotriene D4-induced contraction in guinea-pig airways | |
| Selvaraj et al. | Effect of Glycosin alkaloid from Rhizophora apiculata in non-insulin dependent diabetic rats and its mechanism of action: In vivo and in silico studies | |
| Thabet et al. | Validation of the antihyperglycaemic and hepatoprotective activity of the flavonoid rich fraction of Brachychiton rupestris using in vivo experimental models and molecular modelling | |
| CN106916133B (zh) | 一种具有抑制ptp1b活性的间苯三酚衍生物及其制备方法、应用 | |
| CN104163844B (zh) | 甾体烯酮类化合物蕨藻烯酮及其制备和用途 | |
| CN107802626A (zh) | 降血糖组合物及其制备方法、用途 | |
| CN107805269A (zh) | Dictyopterisinf及其制备糖尿病或肥胖症药物中的应用 | |
| Wang et al. | Studies on the key constituents and the related mechanisms of Clerodendranthus spicatus in the treatment of diabetes based on network pharmacology | |
| Cristians et al. | Hypoglycemic activity of extracts and compounds from the leaves of Hintonia standleyana and H. latiflora: potential alternatives to the use of the stem bark of these species | |
| CN107674108A (zh) | 豆甾烷型甾体类化合物在制备糖尿病或肥胖症药物中的应用 | |
| CN104224813B (zh) | 一种药物组合物及其制备方法与用途 | |
| CN105949104B (zh) | 一种血红素酸酯化的链状二萜类化合物的用途 | |
| CN106749147B (zh) | 降血糖化合物及其制备方法、用途 | |
| CN106748664A (zh) | 具有降血糖作用的新联苄类天然药物及其用途 | |
| CN101474314A (zh) | 儿茶素在制药中的应用 | |
| CN106748778A (zh) | 具有降血糖作用的一种新联苄类天然药物及其制备方法和用途 | |
| CN107652347A (zh) | 化合物DictyopterisinI及其在制备糖尿病或肥胖症药物中的用途 | |
| CN100478015C (zh) | 一种治疗过敏性鼻炎的中药组合物及其制备方法 | |
| CN105384717B (zh) | 甘松新酮类化合物及其制备方法与应用 | |
| Sulastri et al. | Antidiabetic formulation development based on natural materials as α-glucosidase enzyme inhibitor | |
| CN106580933B (zh) | 3,5-二羟基-2-[3,7-二甲基-2(反式),6-辛二烯基]-联苄的用途 | |
| CN107722098A (zh) | 化合物dictyopterisinc及其在制备糖尿病或肥胖症药物中的应用 | |
| CN105646151A (zh) | 一种炔类化合物及其制备方法和该化合物的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211201 Address after: Zone E, 23rd floor, block D, building 1, No. 6, Jianguomenwai street, Chaoyang District, Beijing 100020 Patentee after: Yilian housekeeper health management (Beijing) Co.,Ltd. Address before: 999 No. 330031 Jiangxi province Nanchang Honggutan University Avenue Patentee before: Nanchang University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230403 Address after: 12A02, 11th Floor, No. C2 East Third Ring North Road, Chaoyang District, Beijing, 100020 Patentee after: Beijing Traditional Chinese Medicine Alliance Health Technology Co.,Ltd. Address before: Zone E, 23rd floor, block D, building 1, No. 6, Jianguomenwai street, Chaoyang District, Beijing 100020 Patentee before: Yilian housekeeper health management (Beijing) Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210105 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |